Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study

被引：0
|
作者：
Nazha, Bassel
Brown, Jacqueline T.
Liu, Yuan
Kissick, Haydn
Carthon, Bradley Curtis
Kucuk, Omer
Harik, Lara R.
Narayan, Vikram M.
Joshi, Shreyas S.
Bilen, Mehmet Asim
机构：
[1] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA USA
[2] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA
[3] Emory Univ, Dept Urol, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Pathol, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Urol, Atlanta, GA USA
[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4615
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer
    Petrylak, Daniel P.
    Chia, Yen Lin
    Yu, Evan Y.
    Powles, Thomas
    Flaig, Thomas W.
    Loriot, Yohann
    O'Donnell, Peter H.
    Heath, Elisabeth I.
    Kojima, Takahiro
    Park, Se Hoon
    Sonpavde, Guru P.
    Picus, Joel
    Matsubara, Nobuaki
    Obara, Wataru
    Chudasama, Vaishali
    Poondru, Srinivasu
    Harrison, Michael
    Kim, Eric
    Brancato, Sam Joseph
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
    Mar, Nataliya
    Friedlander, Terence W.
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Bilen, Mehmet Asim
    Balar, Arjun Vasant
    Henry, Elizabeth
    Srinivas, Sandy
    Rosenberg, Jonathan E.
    Petrylak, Daniel Peter
    Burgess, Earle Frederick
    Merchan, Jaime R.
    Tagawa, Scott T.
    Carret, Anne-Sophie
    Steinberg, Joyce Leta
    Chaney, Marya F.
    Milowsky, Matthew, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
    van der Heijden, M. S.
    Gupta, S.
    Galsky, M. D.
    Derleth, C.
    Steinberg, J.
    Kataria, R.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
  • [24] A Phase II Study of Gemcitabine and Irinotecan in Patients With Locally Advanced or Metastatic Bladder Cancer
    Chaudhary, Uzair B.
    Verma, Nitin
    Keane, Thomas
    Gudena, Vinay
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 188 - 193
  • [25] Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer
    Tabagari, D.
    Nemsadze, G.
    Janjalia, M.
    Jincharadze, M.
    Shan, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
    Kasi, Anup
    Phadnis, Milind A.
    Al-Rajabi, Raed Moh'd Taiseer
    Baranda, Joaquina Celebre
    Li, Haoran
    Carroll, Erin
    Belcher, Cathey
    Bradbury, Shannon
    Collins, Zachary
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS719 - TPS719
  • [27] EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
    Bruce, Justine Yang
    Pusztai, Lajos
    Braiteh, Fadi S.
    Gorla, Seema Rao
    Wu, Chunzhang
    Baranda, Joaquina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Treatment of locally advanced and metastatic bladder cancer
    Khochikar, Makarand V.
    INDIAN JOURNAL OF UROLOGY, 2008, 24 (01) : 84 - 94
  • [29] Determining fi tness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments
    Russell, B. M.
    Fein, D. E. C.
    Bellmunt, J.
    ESMO OPEN, 2024, 9 (11)
  • [30] Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter
    D Papamichael
    CJ Gallagher
    RTD Oliver
    PW Johnson
    J Waxman
    British Journal of Cancer, 1997, 75 : 606 - 607
12345